Innoviva (INVA) EBT (2010 - 2026)
Innoviva posted quarterly EBT of $234.6 million for Q1 2026, up 707.85% year-on-year from $29.0 million in Q1 2025, and up 1796.9% on a QoQ basis from -$13.8 million in Q4 2025.
Innoviva (INVA) has 17 years of EBT data on file, last reported at $234.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 707.85% year-over-year to $234.6 million; the trailing twelve-month figure through Mar 2026 stood at $391.2 million (up 579.6% YoY), and the FY2025 full-year result was $327.1 million, up 775.38% from the prior year.
- EBT for Q1 2026 stood at $234.6 million, up from -$13.8 million in the prior quarter.
- Across five years, EBT topped out at $286.4 million in Q3 2022 and bottomed at -$39.3 million in Q2 2024.
- The 5-year median for EBT is $20.5 million (2022), against an average of $48.4 million.
- The widest annual swing landed in 2024, when EBT tumbled 776.64%; it then soared 1328.19% in 2025.
- A 5-year view of EBT shows it stood at -$10.3 million in 2022, then surged by 36.31% to -$6.6 million in 2023, then plunged by 60.22% to -$10.5 million in 2024, then tumbled by 31.16% to -$13.8 million in 2025, then surged by 1796.9% to $234.6 million in 2026.
- The last three EBT figures came in at $234.6 million (Q1 2026), -$13.8 million (Q4 2025), and $97.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 234.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 234.56 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 97.82 Mn |
| Jun 30, 2025 | 72.60 Mn |
| Mar 31, 2025 | -38.59 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 6.85 Mn |
| Jun 30, 2024 | -39.28 Mn |
| Mar 31, 2024 | 45.12 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 85.95 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 41.14 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 286.42 Mn |
| Jun 30, 2022 | 20.50 Mn |
| Mar 31, 2022 | 44.72 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 123.18 Mn |
| Jun 30, 2021 | 136.18 Mn |
| Mar 31, 2021 | 129.43 Mn |
| Dec 31, 2020 | 90.76 Mn |
| Sep 30, 2020 | 50.49 Mn |
| Jun 30, 2020 | 118.12 Mn |
| Mar 31, 2020 | 94.88 Mn |
| Dec 31, 2019 | 70.27 Mn |
| Sep 30, 2019 | 57.61 Mn |
| Jun 30, 2019 | 56.49 Mn |
| Mar 31, 2019 | 48.53 Mn |
| Dec 31, 2018 | 73.14 Mn |
| Sep 30, 2018 | 50.17 Mn |
| Jun 30, 2018 | 56.62 Mn |
| Mar 31, 2018 | 30.33 Mn |
| Dec 31, 2017 | 30.31 Mn |
| Sep 30, 2017 | 34.03 Mn |
| Jun 30, 2017 | 35.93 Mn |
| Mar 31, 2017 | 16.80 Mn |
| Dec 31, 2016 | 24.83 Mn |
| Sep 30, 2016 | 14.98 Mn |
| Jun 30, 2016 | 12.88 Mn |
| Mar 31, 2016 | 4.47 Mn |
| Dec 31, 2015 | 4.30 Mn |
| Sep 30, 2015 | -4.58 Mn |
| Jun 30, 2015 | -7.81 Mn |
| Mar 31, 2015 | -10.67 Mn |
| Dec 31, 2014 | -15.93 Mn |
| Sep 30, 2014 | -21.55 Mn |
| Jun 30, 2014 | -19.87 Mn |
| Mar 31, 2014 | -16.18 Mn |
| Dec 31, 2013 | -8.89 Mn |
| Sep 30, 2013 | -9.45 Mn |
| Jun 30, 2013 | -1.54 Mn |
| Mar 31, 2013 | -35.94 Mn |
| Dec 31, 2012 | -43.47 Mn |
| Sep 30, 2012 | -34.69 Mn |
| Jun 30, 2012 | -37.12 Mn |
| Mar 31, 2012 | 84.59 Mn |
| Dec 31, 2011 | -37.01 Mn |
| Sep 30, 2011 | -30.63 Mn |
| Jun 30, 2011 | -25.05 Mn |
| Mar 31, 2011 | -22.81 Mn |
| Dec 31, 2010 | -19.44 Mn |
| Sep 30, 2010 | -21.22 Mn |
| Jun 30, 2010 | -20.81 Mn |